API Synthesis and Manufacturing, Large Molecule

Nanoparticle-based systems present many advantages for the delivery of current and emerging biological drugs.

A surge in capacity in contract microbial and mammalian cell-culture is underway to meet rising production needs for biopharmaceuticals.

Reflecting strong growth prospects for certain biologic-based drugs, the biotechnology and pharmaceutical majors are proceeding with a strategy of expanding their internal manufacturing networks and partnering with select contract manufacturing organizations (CMOs).

USP ensures the microbiological quality of products by way of the development, proposal, and acceptance of general information chapters.